Skip to content

Study · Not a test of the peptide alone · 1999

9 results

Efficacy of repeated cycles of chemo-immunotherapy with thymosin alpha1 and interleukin-2 after intraperitoneal 5-fluorouracil delivery.

Silecchia G, Guarino E, Sinibaldi-Vallebona P, Pierimarchi P, Restuccia A, Spaziani E, Bernard P, Tuthill C, Garaci E, Rasi G

Cancer immunology, immunotherapy : CII1 Jul 1999Cited by 16 (Europe PMC)

PMID10431686 (opens in a new tab)PMCIDPMC11037136 (opens in a new tab)DOI10.1007/s002620050562 (opens in a new tab)PepBankPUB-10431686
Source linkPubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone9

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In rats with colorectal liver metastases, two cycles of 5-FU, thymosin alpha1 and IL-2 increased average survival time compared with one cycle.

    In plain wordsIn rats with liver metastases, two cycles of a three-drug regimen gave longer survival than one cycle of the regimen.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseSurvival time, two cycles versus one cycle of triple therapy
    Study

    ratn: not reported in source

    DHD/K12 colorectal liver metastases in syngeneic BDIX rats
    Comparator
    One cycle of triple therapy
    Outcome group
    Mortality · Cancer

    Source sentences

    Summary
    We show here that two cycles of a triple chemo-immunotherapy regimen significantly increased the average survival time compared to one cycle, and compared to untreated controls or those treated with two cycles of 5-FU alone.
    1 context sentence
    Summary · context
    We have used chemo-immunotherapy with 5-fluorouracil (5-FU), thymosin alpha1 (T alpha1) and interleukin-2 (IL-2) to treat multiple liver metastases from colorectal cancer induced by DHD/K12 cells in syngeneic BDIX rats, comparing one and two cycles of treatment, and different treatment combinations.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 02AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In rats with colorectal liver metastases, two cycles of 5-FU, thymosin alpha1 and IL-2 increased average survival time compared with untreated controls.

    In plain wordsIn rats with liver metastases, two cycles of a three-drug regimen gave longer survival than no treatment.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseSurvival time, two cycles of triple therapy versus untreated controls
    Study

    ratn: not reported in source

    DHD/K12 colorectal liver metastases in syngeneic BDIX rats
    Comparator
    Untreated controls
    Outcome group
    Mortality · Cancer

    Source sentences

    Summary
    We show here that two cycles of a triple chemo-immunotherapy regimen significantly increased the average survival time compared to one cycle, and compared to untreated controls or those treated with two cycles of 5-FU alone.
    1 context sentence
    Summary · context
    We have used chemo-immunotherapy with 5-fluorouracil (5-FU), thymosin alpha1 (T alpha1) and interleukin-2 (IL-2) to treat multiple liver metastases from colorectal cancer induced by DHD/K12 cells in syngeneic BDIX rats, comparing one and two cycles of treatment, and different treatment combinations.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 03AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In rats with colorectal liver metastases, two cycles of 5-FU, thymosin alpha1 and IL-2 increased average survival time compared with two cycles of 5-FU alone.

    In plain wordsIn rats with liver metastases, two cycles of a three-drug regimen gave longer survival than two cycles of 5-FU alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseSurvival time, two cycles of triple therapy versus two cycles of 5-FU
    Study

    ratn: not reported in source

    DHD/K12 colorectal liver metastases in syngeneic BDIX rats
    Comparator
    Two cycles of 5-FU alone
    Outcome group
    Mortality · Cancer

    Source sentences

    Summary
    We show here that two cycles of a triple chemo-immunotherapy regimen significantly increased the average survival time compared to one cycle, and compared to untreated controls or those treated with two cycles of 5-FU alone.
    1 context sentence
    Summary · context
    We have used chemo-immunotherapy with 5-fluorouracil (5-FU), thymosin alpha1 (T alpha1) and interleukin-2 (IL-2) to treat multiple liver metastases from colorectal cancer induced by DHD/K12 cells in syngeneic BDIX rats, comparing one and two cycles of treatment, and different treatment combinations.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  4. 04AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In rats with colorectal liver metastases, two rats given two cycles of triple therapy were cured at 150 days, and all other rats died before then.

    In plain wordsIn rats with liver metastases, two rats given the three-drug regimen were cured at 150 days; all other rats died earlier.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableCure at 150 days
    Study

    ratn: not reported in source

    DHD/K12 colorectal liver metastases in syngeneic BDIX rats
    Outcome group
    Mortality · Cancer

    Source sentences

    Summary
    At 150 days, two rats treated with two cycles of triple therapy were cured, showing no signs of cancer at autopsy; all the other rats died before this time.
    1 context sentence
    Summary · context
    We have used chemo-immunotherapy with 5-fluorouracil (5-FU), thymosin alpha1 (T alpha1) and interleukin-2 (IL-2) to treat multiple liver metastases from colorectal cancer induced by DHD/K12 cells in syngeneic BDIX rats, comparing one and two cycles of treatment, and different treatment combinations.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  5. 05AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In rats with colorectal liver metastases, the triple regimen of 5-FU, thymosin alpha1 and IL-2 resulted in significantly fewer extra-hepatic metastases than in controls.

    In plain wordsIn rats with liver metastases, the three-drug regimen led to fewer metastases outside the liver than in controls.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseExtra-hepatic metastases versus controls
    Study

    ratn: not reported in source

    DHD/K12 colorectal liver metastases in syngeneic BDIX rats
    Comparator
    Controls
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Triple chemo-immunotherapy resulted in significantly fewer extra-hepatic metastases than in the controls and in those treated with 5-FU only.
    1 context sentence
    Summary · context
    We have used chemo-immunotherapy with 5-fluorouracil (5-FU), thymosin alpha1 (T alpha1) and interleukin-2 (IL-2) to treat multiple liver metastases from colorectal cancer induced by DHD/K12 cells in syngeneic BDIX rats, comparing one and two cycles of treatment, and different treatment combinations.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  6. 06AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In rats with colorectal liver metastases, the triple regimen of 5-FU, thymosin alpha1 and IL-2 resulted in significantly fewer extra-hepatic metastases than 5-FU only.

    In plain wordsIn rats with liver metastases, the three-drug regimen led to fewer metastases outside the liver than 5-FU alone.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseExtra-hepatic metastases versus 5-FU only
    Study

    ratn: not reported in source

    DHD/K12 colorectal liver metastases in syngeneic BDIX rats
    Comparator
    5-FU only
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Triple chemo-immunotherapy resulted in significantly fewer extra-hepatic metastases than in the controls and in those treated with 5-FU only.
    1 context sentence
    Summary · context
    We have used chemo-immunotherapy with 5-fluorouracil (5-FU), thymosin alpha1 (T alpha1) and interleukin-2 (IL-2) to treat multiple liver metastases from colorectal cancer induced by DHD/K12 cells in syngeneic BDIX rats, comparing one and two cycles of treatment, and different treatment combinations.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  7. 07AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In rats with colorectal liver metastases, two cycles of the triple regimen significantly increased the absolute number of peripheral T cells expressing IL-2 receptor compared with controls.

    In plain wordsIn rats with liver metastases, two cycles of the three-drug regimen raised IL-2 receptor T cell numbers compared with controls.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreasePeripheral T cells expressing IL-2 receptor
    Study

    ratn: not reported in source

    DHD/K12 colorectal liver metastases in syngeneic BDIX rats
    Comparator
    Controls
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Further, we found that two cycles of triple treatment significantly increased the absolute number of peripheral T cells expressing IL-2 receptor, CD4 and CD8 compared to controls.
    1 context sentence
    Summary · context
    We have used chemo-immunotherapy with 5-fluorouracil (5-FU), thymosin alpha1 (T alpha1) and interleukin-2 (IL-2) to treat multiple liver metastases from colorectal cancer induced by DHD/K12 cells in syngeneic BDIX rats, comparing one and two cycles of treatment, and different treatment combinations.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  8. 08AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In rats with colorectal liver metastases, two cycles of the triple regimen significantly increased the absolute number of peripheral CD4 T cells compared with controls.

    In plain wordsIn rats with liver metastases, two cycles of the three-drug regimen raised CD4 T cell numbers compared with controls.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreasePeripheral CD4 T cells
    Study

    ratn: not reported in source

    DHD/K12 colorectal liver metastases in syngeneic BDIX rats
    Comparator
    Controls
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Further, we found that two cycles of triple treatment significantly increased the absolute number of peripheral T cells expressing IL-2 receptor, CD4 and CD8 compared to controls.
    1 context sentence
    Summary · context
    We have used chemo-immunotherapy with 5-fluorouracil (5-FU), thymosin alpha1 (T alpha1) and interleukin-2 (IL-2) to treat multiple liver metastases from colorectal cancer induced by DHD/K12 cells in syngeneic BDIX rats, comparing one and two cycles of treatment, and different treatment combinations.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  9. 09AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In rats with colorectal liver metastases, two cycles of the triple regimen significantly increased the absolute number of peripheral CD8 T cells compared with controls.

    In plain wordsIn rats with liver metastases, two cycles of the three-drug regimen raised CD8 T cell numbers compared with controls.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreasePeripheral CD8 T cells
    Study

    ratn: not reported in source

    DHD/K12 colorectal liver metastases in syngeneic BDIX rats
    Comparator
    Controls
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Further, we found that two cycles of triple treatment significantly increased the absolute number of peripheral T cells expressing IL-2 receptor, CD4 and CD8 compared to controls.
    1 context sentence
    Summary · context
    We have used chemo-immunotherapy with 5-fluorouracil (5-FU), thymosin alpha1 (T alpha1) and interleukin-2 (IL-2) to treat multiple liver metastases from colorectal cancer induced by DHD/K12 cells in syngeneic BDIX rats, comparing one and two cycles of treatment, and different treatment combinations.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.